Liposome Technology
Executive Summary
Phase III trials of Amphocil amphotericin B colloidal dispersion are "about to begin," VP-Research Francis Martin, PhD, tells the Mabon Securities Drug Delivery Conference Feb. 19 in New York City. The company forecasts an NDA filing for the first quarter of 1993 for treatment of life-threatening fungal infections in patients who have failed conventional therapy. A second NDA, for the "Stealth" liposome encapsulated doxorubicin Doxil for the treatment of Kaposi's sarcoma, is slated for mid-1993, Martin says.